Promoting CRISPRa for Targeted Treatment of Epilepsy

Wagnon, Jacy L.

doi:10.1177/1535759720935825

Cited by 4 publications

(2 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Another primary concern is passing through the blood-brain barrier (BBB) system, as this physiological barrier holds the cerebral microenvironment very tightly and isolates it completely from other segments of the human body to protect this intricate neural network system. Therefore, a well-targeted approach is required to access the BBB without disrupting its integrity and biological functioning [172]. Many approaches, such as micro dialysis and brain perfusion studies, have not performed well, though nanoparticle-based targeted delivery has shown some positive results [173][174][175].…”

Section: Challenges Associated With the Application Of Crispr In Neur...mentioning

confidence: 99%

Recent Updates on Corticosteroid-Induced Neuropsychiatric Disorders and Theranostic Advancements through Gene Editing Tools

et al. 2023

View full text Add to dashboard Cite

The vast use of corticosteroids (CCSs) globally has led to an increase in CCS-induced neuropsychiatric disorders (NPDs), a very common manifestation in patients after CCS consumption. These neuropsychiatric disorders range from depression, insomnia, and bipolar disorders to panic attacks, overt psychosis, and many other cognitive changes in such subjects. Though their therapeutic importance in treating and improving many clinical symptoms overrides the complications that arise after their consumption, still, there has been an alarming rise in NPD cases in recent years, and they are seen as the greatest public health challenge globally; therefore, these potential side effects cannot be ignored. It has also been observed that many of the neuronal functional activities are regulated and controlled by genomic variants with epigenetic factors (DNA methylation, non-coding RNA, and histone modeling, etc.), and any alterations in these regulatory mechanisms affect normal cerebral development and functioning. This study explores a general overview of emerging concerns of CCS-induced NPDs, the effective molecular biology approaches that can revitalize NPD therapy in an extremely specialized, reliable, and effective manner, and the possible gene-editing-based therapeutic strategies to either prevent or cure NPDs in the future.

show abstract

Section: Challenges Associated With the Application Of Crispr In Neur...mentioning

confidence: 99%

Recent Updates on Corticosteroid-Induced Neuropsychiatric Disorders and Theranostic Advancements through Gene Editing Tools

et al. 2023

View full text Add to dashboard Cite

show abstract

“…In a model of temporal lobe epilepsy, findings have demonstrated a decrease in spontaneous generalized tonic–clonic seizures as well as transcriptome changes related to chronic epilepsy. This work demonstrates that CRISPR is also a viable epilepsy therapy strategy [ 40 ]. Additionally, cellular therapy is one type of regenerative medicine that uses stem cells to repair a site of the body that has been diseased or damaged.…”

Section: The Rise Of Seizures In Brain Areasmentioning

confidence: 99%

hUMSC vs. hUMSC–Exosome: Which One Is Better for Epilepsy?

et al. 2022

View full text Add to dashboard Cite

Epilepsy is a disorder characterized by abnormal brain cell activity that results in seizures. It causes progressive damage to neurons. Epilepsy treatment currently focuses mostly on symptoms, which also have risks of unwanted side effects. There is currently no effective treatment to prevent epileptogenesis and the resulting neural damage. Human Umbilical Cord Mesenchymal Stem Cell (hUMSC) and exosome therapy are examples of cellular therapies that may be used to treat degenerative diseases, such as epilepsy, or cell damage. However, there is still little research on the use of hUMSCs or hUMSC–exosomes for treating epilepsy. Hence, the purpose of this paper is to compare the potential and risk of hUMSCs and hUMSC–exosomes as therapies for epilepsy. This article provides a brief summary of hUMSCs and hUMSC–exosomes in multiple aspects, such as the isolation and purification method, the mechanism of action, immunological compatibility, tumorigenicity, the risk of transmitting disease, stability upon storage, the potential of new composition with other substances, and also ethical and political issues. We conclude that hUMSCs and hUMSC–exosomes have therapeutic potential for epilepsy, with hUMSC–exosomes being safer due to their reduced immunogenicity.

show abstract